Trial Profile
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Cardiomyopathies; Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 16 Mar 2020 New trial record